WORLD PEPTIDEFOUNDATION
← Master Registry

Published peptide research references

Satoreotide tetraxetan

Identity watchlist — review pending

4 approved source records with original-source links. Source verification confirms the reference and its connection to this record; it does not certify every scientific conclusion or establish safety or efficacy.

Approved source records

  1. A phase I/II study of the safety and efficacy of [(177)Lu]Lu-satoreotide tetraxetan in advanced somatostatin receptor-positive neuroendocrine tumours.

    DOI: 10.1007/s00259-023-06383-1

    Source identity and connection checked by Codex (AI).

  2. Dosimetry and pharmacokinetics of [(177)Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours.

    DOI: 10.1007/s00259-024-06682-1

    Source identity and connection checked by Codex (AI).

  3. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist (177)Lu-Satoreotide Tetraxetan.

    DOI: 10.1158/1078-0432.ccr-19-1026

    Source identity and connection checked by Codex (AI).

  4. The Role of [177Lu] Lu-Satoreotide Tetraxetan in Somatostatin Receptor-Positive Neuroendocrine Tumors.

    DOI: 10.1053/j.semnuclmed.2025.07.002

    Source identity and connection checked by Codex (AI).

Legacy research context

Context from the legacy curated dataset. Its counts describe that dataset and are separate from the live approved source records above.

Researchers represented

  • Schürrle SB
  • Eberlein U
  • Ansquer C
  • Beauregard JM
  • Durand-Gasselin L
  • Grønbæk H
  • Haug A
  • Hicks RJ
  • Lenzo NP
  • Navalkissoor S
  • Nicolas GP
  • Pais B
  • Volteau M
  • Wild D
  • McEwan A
  • Lassmann M
  • Pennestri D
  • Reidy-Lagunes D
  • Pandit-Taskar N
  • O'Donoghue JA
  • Krebs S
  • Staton KD
  • Lyashchenko SK
  • Lewis JS
  • Raj N
  • Gönen M
  • Lohrmann C
  • Bodei L
  • Weber WA
  • Shekhda KM